Analysis of the key themes driving private equity deal activity reveals that orphan designated drugs accounted for 4 pharmaceutical deals announced in Q3 2023, worth a total value of $274.7m. The $250m investment by Qatar Investment Authority in BridgeBio Pharma was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes and the Private Equity deal activity are included in GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, orphan designated drugs-related deal activity decreased by 49% in Q3 2023 compared with the previous quarter’s total of $535.3m and fell by 77% as compared to Q3 2022. Related deal volume decreased by 43% in Q3 2023 versus the previous quarter and was 77% lower than in Q3 2022.
The top-ranked legal advisors supporting these private equity deals in Q3 2023 were CMS Legal Services EEIG; Cooley; Goodwin Procter with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.